Related Experiment Video
Updated: Aug 22, 2026
Establishment and Analysis of Tumor Slice Explants As a Prerequisite for Diagnostic Testing
Published on: November 29, 2018
Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal
Benjamin Heckelmann1, Daniel Fetzner1, Olga Lapshyna1
1Department of Surgery, University of Luebeck, Luebeck, Germany.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is characterized by chemotherapy resistance, partly driven by its dense and heterogeneous tumor microenvironment (TME). Since most preclinical PDAC models inadequately capture the tissue architecture, their translational value for therapeutic testing remains limited. This study investigated organotypic tissue slice cultures (OTSCs), which preserve the multicellular tissue architecture, as a rapid platform for personalized ex vivo drug response profiling. OTSCs were generated from 27 resected PDAC specimens. Following workflow establishment and quality control, ex vivo drug profiling was performed in 15 patients using gemcitabine, gemcitabine plus paclitaxel, and FOLFIRINOX. Treatment response was assessed by quantitative digital pathology, and an ex vivo sensitivity score (EVSS) was defined. Clinical correlations with longitudinal follow-up were assessed in ten patients. OTSCs preserved tissue architecture and revealed interpatient heterogeneity. In exploratory analyses of clinically matched patients, ex vivo sensitivity was associated with prolonged PFS (median 445 vs. 141 days, log-rank p = 0.0027; HR per 10 EVSS points 0.625; 95% CI 0.484-0.807, p = 0.00032), while lower preoperative CA 19-9 levels and higher GATA6 expression were associated with higher EVSS and longer overall survival. OTSC-based profiling enables rapid, patient-specific drug response assessment in PDAC and supports evaluation as a functional stratification tool.
Insights
Organotypic tissue slice cultures (OTSCs) offer a rapid, patient-specific platform for assessing pancreatic ductal adenocarcinoma (PDAC) drug responses. This approach preserves tissue architecture and shows promise for personalized cancer therapy.
Area of Science:
- Oncology
- Translational Medicine
- Cancer Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) exhibits significant chemotherapy resistance, often attributed to its complex tumor microenvironment (TME).
- Existing preclinical models frequently fail to replicate PDAC's tissue architecture, limiting their utility in therapeutic testing.
- There is a critical need for advanced models that accurately reflect PDAC's heterogeneity for effective drug screening.
Purpose of the Study:
- To evaluate organotypic tissue slice cultures (OTSCs) as a rapid, patient-specific ex vivo platform for profiling drug responses in PDAC.
- To establish and validate a workflow for generating and analyzing OTSCs from patient-derived tumors.
- To correlate ex vivo drug sensitivity with clinical outcomes in PDAC patients.
Main Methods:
- OTSCs were established from 27 resected PDAC specimens, preserving native tissue architecture.
- Ex vivo drug profiling was conducted on 15 patients using standard chemotherapy regimens (gemcitabine, gemcitabine plus paclitaxel, FOLFIRINOX).
- Quantitative digital pathology assessed treatment response, leading to the definition of an ex vivo sensitivity score (EVSS); clinical correlations were analyzed in ten patients.
Main Results:
- OTSCs successfully preserved PDAC tissue architecture and demonstrated significant interpatient heterogeneity.
- Ex vivo sensitivity in clinically matched patients correlated with prolonged progression-free survival (PFS) (median 445 vs. 141 days).
- Lower preoperative CA 19-9 levels and higher GATA6 expression were associated with increased EVSS and longer overall survival.
Conclusions:
- OTSC-based profiling provides a rapid and patient-specific method for assessing drug responses in PDAC.
- This platform facilitates the evaluation of personalized therapeutic strategies and holds potential as a functional stratification tool for PDAC patients.
- The study highlights the translational value of OTSC models in understanding PDAC heterogeneity and guiding treatment decisions.
